Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections.
As has been established in rabbits, (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) is superior to 5-iodo-2'-deoxyuridine (IDU) in the topical treatment of epithelial HSV-1 (herpes simplex virus type 1) keratitis, and superior to 5-trifluoromethyl-2'-deoxyuridine (TFT) in the topical treatment of deep stromal HSV-1 keratitis and HSV-1 uveitis. BVDU 0.1% eye drops have also proven efficacious in the treatment of patients with dendritic corneal ulcers, geographic corneal ulcers and stromal keratitis, and combined treatment of BVDU 0.1% eye drops with oral BVDU at 375 mg/day for 5 days led to a prompt healing of keratouveitis and skin lesions in patients with ophthalmic herpes zoster.
D000818:Animals; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006561:Herpes Simplex / Q000188:drug therapy*; D006563:Herpes Zoster Ophthalmicus / Q000188:drug therapy*; D006801:Humans; D007634:Keratitis / Q000188:drug therapy*; D007635:Keratitis, Dendritic / Q000188:drug therapy; D011817:Rabbits; D014605:Uveitis / Q000188:drug therapy*
C020235:brivudine; D001973:Bromodeoxyuridine